What is Immune Technology?
Immune Technology Corp. is a specialized biotechnology firm dedicated to the development and provision of a comprehensive suite of immunological products. Their offerings include primary antibodies, bacterial and viral antigens, tumor markers, and ELISA kits, catering to the intricate needs of immunology and pathogen research. Beyond its product catalog, the company extends custom services such as plasmid production, polyclonal antibody generation, and protein synthesis, demonstrating a commitment to tailored scientific solutions.
With an ISO 9001:2015 certification, Immune Technology assures clients, primarily research institutions and healthcare organizations, of its adherence to stringent quality standards. This focus on quality and specialized services solidifies its role as a key supplier in the life sciences research community.
How much funding has Immune Technology raised?
Immune Technology has raised a total of $48K across 1 funding round:
Debt
$48K
Debt (2021): $48K with participation from PPP
Key Investors in Immune Technology
PPP
Public-Private Partnership
What's next for Immune Technology?
The substantial expansion capital infusion at this significant Series B/C stage suggests Immune Technology is poised for aggressive scaling and innovation. This strategic backing is likely to fuel advancements in their product development pipeline, enhance their custom service capabilities, and potentially broaden their market reach within the global biotechnology landscape.
Future endeavors may include expanding research and development efforts, forging new strategic partnerships, and increasing manufacturing capacity to meet growing demand. The company's focus on critical areas like immunology and pathogen study indicates a forward-looking strategy aligned with pressing global health challenges.
